Comparative Pharmacology
Head-to-head clinical analysis: ANTHIM versus BENLYSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTHIM versus BENLYSTA.
ANTHIM vs BENLYSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oblimersen is an antisense oligonucleotide that inhibits the production of Bcl-2 protein, promoting apoptosis in cancer cells.
Belimumab is a human IgG1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLyS, also known as BAFF), inhibiting its activity. BLyS is a cytokine that promotes B-cell survival and differentiation. By binding BLyS, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
800 mg IV over 90 minutes, then 400 mg IV over 90 minutes at 2 and 4 weeks post-first dose.
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
None Documented
None Documented
Terminal elimination half-life: approximately 21 days (range 12–31 days); supports monthly dosing for post-exposure prophylaxis
Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
Renal: approximately 50% as unchanged drug; biliary/fecal: minimal (<10%)
Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody